Сравнительный анализ туристских потоков из Приморского края в Китай
Фундаментальные исследования (Fundamental Research) – January 01, 2014
Source: OpenAlex
Summary
A single dose of psilocybin can alleviate anxiety for up to three months in advanced cancer patients, or over a year in healthy individuals. Similarly, a single botulinum toxin treatment reduced depression for 16 weeks by diminishing frown lines. Ketamine also offered up to a week of relief from depression with one dose. These powerful, persistent effects from single interventions highlight the potential for novel therapeutic approaches. Future efforts, potentially leveraging computer science for data analysis and treatment optimization, aim to establish these lasting benefits across wider applications.
Abstract
Recent clinical trials suggest that 3 single biological treatments have effects that persist. Based on research showing that the muscles involved in facial expressions can feed back to influence mood, a single trial diminishing glabella frown lines with botulinum toxin demonstrated a significant antidepressant effect for 16 weeks. Based primarily on research with animal models of depression suggesting that glutamate may be involved in depression, the N-methyl-D-aspartate antagonist ketamine has been tested in several trials. A single dose decreased depression for up to a week. The reported effects of the use of mushrooms containing psilocybin by a number of cultures around the world has stimulated several trials showing beneficial effects of a single dose of psilocybin for over a year in healthy people, and for up to 3 months in patients with anxiety disorders who have advanced cancer. This article discusses these studies, their rationale, their possible mechanisms of action, the future clinical research required to establish these therapies and the basic research required to optimize single treatments that have lasting effects.